MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Core Insights - MAIA Biotechnology, Inc. has reported positive efficacy data from its Phase 2 clinical trial, THIO-101, which evaluates ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients who have failed multiple standard therapies [1][2] Group 1: Efficacy Data - The Phase 2 trial THIO-101 shows a progression-free survival (PFS) of 5.6 months, which is more than double the standard of care PFS of 2.5 months [2][6] - The estimated median overall survival (OS) is reported at 17.8 months, with a 95% confidence interval lower bound of 12.5 months [6] Group 2: Drug Mechanism and Development - Ateganosine is a first-in-class investigational telomere-targeting agent that induces telomerase-dependent telomeric DNA modification and selective cancer cell death [3] - The drug activates both innate and adaptive immune responses, leading to significant tumor regression in advanced cancer models [3] Group 3: Clinical Trial Design - THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition [4] - The trial has two primary objectives: to evaluate the safety and tolerability of ateganosine and to assess its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [4] Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with ateganosine being its lead program aimed at treating NSCLC patients with telomerase-positive cancer cells [7]